MedTrace Logo

Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery

NCT03959969 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-04-01

No results posted yet for this study

Summary

This is a randomized controlled trial assessing the utility of an educational video on pain management after a cesarean section to reduce opioid use. The educational video will be shown during the patient's postpartum stay and the amount of opioid and adjunct medications will be assessed in those who watched the video compared to those who received the standard of care discharge instructions without the video. Participants will be contacted 7 and 14 days after cesarean birth (post operative day number 7 and number 14) to complete a telephone survey on their overall pain management and to determine how many opioid tablets have been used.

Conditions

  • Opioid Use, Unspecified

Interventions

OTHER

Educational video

An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.

OTHER

Standard of care

The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.

DRUG

Ibuprofen

Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.

DRUG

Oxycodone

Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.

Sponsors & Collaborators

  • Medstar Health Research Institute

    lead OTHER

Principal Investigators

  • Sara Iqbal, MD · Medstar Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2019-12-28
Completion
2020-01-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03959969 on ClinicalTrials.gov